|
Diabetes Medication Article
Diabetes Pills
Background Information about Diabetes Pills
Our bodies need glucose as a source of energy for movement, growth, repair, and other functions. When we eat, our bodies break food down into organic compounds, one of which is glucose. But before the cells can use glucose, it must move from the bloodstream into the individual cells. This process requires insulin.
Insulin is produced by the beta cells in the islets of Langerhans in the pancreas. When glucose enters our blood, the pancreas should automatically produce the right amount of insulin to move glucose into our cells. People with type 2 diabetes either produce too little insulin, produce it too late to match the rise in blood glucose, or do not respond correctly to the insulin that is produced. Then glucose builds up in the blood, overflows into the urine, and passes out of the body. This means that the body loses its main source of energy even though the blood contains large amounts of glucose.
Diabetes pills work in one of three ways. They either stimulate the pancreas to release more insulin, increase the body's sensitivity to the insulin that is already present, or slow the breakdown of foods (especially starches) into glucose.
Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat
Byetta Drug News
Byetta Drug
IMPORTANT: Bing News RSS feed has moved!
Bydureon uses technology developed by Alkermes to slowly release exenatide into the bloodstream with one dose a week. The drug won European Commission approval in June. “Bydureon’s approval in the U.S. will not solve Amylin’s current ...
Read moreAmylin, Alkermes Long-Acting Diabetes Drug Wins FDA Approval on Third Try
... lawyers at The Eichholz Law Firm are seeking diabetes patients who were prescribed Byetta and later suffered from kidney failure or pancreatitis. The dangerous drug attorneys are offering free and confidential case evaluations for all those that ...
Read moreSavannah Byetta Lawyers Seeking Individuals with Pancreatitis and Kidney Failure
Bydureon is an injectable, extended-release version of Amylin's older diabetes drug, Byetta, which is injected twice daily. Byetta and Bydureon share an active ingredient, exenatide. Bydureon was approved for sale by European regulators in June.
Read moreFDA Approves Amylin's Bydureon Diabetes Drug
January 27, 2012 — The US Food and Drug Administration (FDA) today approved a once-weekly extended-release formulation of exenatide injection (Bydureon, Amylin Pharmaceuticals) as an adjunct to diet and exercise to improve glycemic control in ...
Read moreOnce-Weekly Exenatide Okayed by FDA for T2DM After Long Look
Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's 7-year old diabetes medicine, Byetta. Bydureon is a once-a-week version of Byetta ...
Read moreAmylin's Long-Delayed Diabetes Drug Gets FDA Nod
Therefore, you only have to give it once a week. Bydureon is "once-a-week Byetta." Many things about this drug are very similar to Byetta. Byetta is a GLP-1 agonist. These drugs work like GLP-1 in the body: They improve insulin secretion ...
Read moreBydureon: An Easy, Effective New Treatment for Type 2 Diabetes
the new drug from Amylin and Alkermes is the first treatment that can be injected as little as once a week. Amylin has been marketing the original form of exenatide (Byetta) as a twice-daily injectable since 2005. About 25 million people in ...
Read moreAmylin, Alkermes Win FDA Approval of Once-Weekly Diabetes Drug
FDA has approved exenatide extended-release for injectable suspension ... vice president of corporate affairs at Amylin, told Drug Topics. “Bydureon is continuously released throughout the week, helping to keep blood-sugar levels under ...
Read moreFDA approves first once-weekly treatment for type 2 diabetes
with the companies finally gaining US Food and Drug Administration (:FDA) approval for their once-weekly type II diabetes treatment, Bydureon (exenatide extended-release for injectable suspension). Bydureon, a glucagon-like peptide-1 (GLP-1 ...
Read more